Real-time t(11;14) and t(14;18) PCR assays provide sensitive and quantitative assessments of minimal residual disease (MRD)

Leukemia

Volumn 13, Issue 11, 1999, Pages 1833-1842

  Olsson, K ^a   Gerard, C J ^a,d   Zehnder, J ^b   Jones, C ^b   Ramanathan, R ^a   Reading, C ^a,e   Hanania, E G ^a,c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Oncosis   (United States)

^d Targeted Genetics Corporation   (United States)

^e Hollis Eden Pharmaceuticals Inc   (United States)

Author keywords

bcl 1 bcl 2; Minimal residual disease (MRD); Non Hodgkin's lymphoma (NHL); Quantitative assessment; Real time PCR; TaqMan assay

Indexed keywords

CD34 ANTIGEN; DNA MARKER;

ARTICLE; CELL LINE; CHROMOSOME BREAKAGE; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 14; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENE CLUSTER; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; NONHODGKIN LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

EID: 0032717189     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401575     Document Type: Article

References (45)

1. Aisenberg AC, Wilkes BM, Jacobson JO. The bcl-2 gene is rearranged in many diffuse B-cell lymphomas. Blood 1988; 71: 969-972.
2. Crescenzi M, Seto M, Herzig GP, Weiss PD, Griffith RC, Korsmeyer SJ. Thermostable DNA polymerase chain amplification of t(14;18) chromosome breakpoints and detection of minimal residual disease. Proc Natl Acad Sci USA 1988; 85: 4869-4873.
3. Graninger WB, Seto M, Boutain B, Goldman P, Korsmeyer SJ. Expression of Bcl-2 and Bcl-2-Ig fusion transcripts in normal and neoplastic cells. J Clin Invest 1987; 80: 1512-1515.
4. Gribben JG, Nadler LM. Detection of minimal residual disease in patients with lymphomas using the polymerase chain reaction. Important Adv Oncol 1994; 117-129.
5. Lambrechts AC, de Ruiter PE, Dorssers LC, vant Veer MB. Detection of residual disease in translocation (14;18) positive non-Hodgkin's lymphoma, using the polymerase chain reaction: a comparison with conventional staging methods. Leukemia 1992; 6: 29-34.
6. Korsmeyer SJ. Chromosomal translocations in lymphoid malignancies reveal novel proto-oncogenes. Annu Rev Immunol 1992; 10: 785-807.
7. Ngan BY, Nourse J, Cleary ML. Detection of chromosomal translocation t(14;18) within the minor cluster region of bcl-2 by polymerase chain reaction and direct genomic sequencing of the enzymatically amplified DNA in follicular lymphomas. Blood 1989; 73: 1759-1762.
8. Weiss LM, Warnke RA, Sklar J, Cleary ML. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. New Engl J Med 1987; 317: 1185-1189.
9. Aguilera NS, Bijwaard KE, Duncan B, Krafft AE, Chu WS, Abbondanzo SL, Lichy JH, Taubenberger JK. Differential expression of cyclin D1 in mantle cell lymphoma and other non-Hodgkin's lymphomas. Am J Pathol 1998; 153: 1969-1976.
10. Avet-Loiseau H, Garand R, Gaillard F, Daviet A, Mellerin MP, Robillard N, Bouyge I, Arcot S, Batzer M, Talmant P, Harousseau JL, Milpied N, Bataille R. Detection of t(11;14) using interphase molecular cytogenetics in mantle cell lymphoma and atypical chronic lymphocytic leukemia. Genes Chromosomes Cancer 1998; 23: 175-182.
11. Fan H, Gulley ML, Gascoyne RD, Horsman DE, Adomat SA, Cho CG. Molecular methods for detecting t(11;14) translocations in mantle-cell lymphomas. Diagn Mol Pathol 1998; 7: 209-214.
12. Nakamura S, Yatabe Y, Kuroda H, Ueda R, Takahashi T, Suchi T, Seto M. Immunostaining of PRAD1/cyclin D1 protein as a marker for the diagnosis of mantle cell lymphoma. Leukemia 1997; 11: 536-537.
13. Ott MM, Bartkova I, Bartek J, Durr A, Fischer L, Ott G, Muller-Hermelink HK, Kreipe H. Cyclin D1 expression in mantle cell lymphoma is accompanied by downregulation of cyclin D3 and is not related to the proliferative activity. Blood 1997; 90: 3154-3159.
14. Pott C, Tiemann M, Linke B, Ott MM, von Hofen M, Bolz I, Hiddemann W, Parwaresch R, Kneba M. Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas. Leukemia 1998; 12: 1630-1637.
15. Griesser H. Applied molecular genetics in the diagnosis of malignant non-Hodgkin's lymphoma. Diagn Mol Pathol 1993; 2: 177-191.
16. Tsujimoto Y, Gorham J, Cossman J, Jaffe E, Croce CM. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 1985; 229: 1390-1393.
17. Chibbar R, Leung K, McCormick S, Ritzkalla K, Strickler J, Staggs R, Poppema S, Brunning RD, McGlennen RC. bcl-1 gene rearrangements in mantle cell lymphoma: a comprehensive analysis of 118 cases, including B-5-fixed tissue, by polymerase chain reaction and Southern transfer analysis. Mod Pathol 1998; 11: 1089-1097.
18. Luthra R, Hai S, Pugh WC. Polymerase chain reaction detection of the t(11;14) translocation involving the bcl-1 major translocation cluster in mantle cell lymphoma. Diagn Mol Pathol 1995; 4: 4-7.
19. Pinyol M, Campo E, Nadal A, Terol MJ, Jares P, Nayach I, Fernandez PL, Piris MA, Montserrat E, Cardesa A. Detection of the bcl-1 rearrangement at the major translocation cluster in frozen and paraffin-embedded tissues of mantle cell lymphomas by polymerase chain reaction. Am J Clin Pathol 1996; 105: 532-537.
20. Andersen NS, Donovan JW, Borus JW, Poor CM, Neuberg D, Aster JC, Nadler LM, Freedman AS, Gribben JC. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood 1997; 90: 4212-4221.
21. Corradini P, Astolfi M, Cherasco C, Ladetto M, Voena C, Caracciolo D, Pileri A, Tarella C. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood 1997; 89: 724-731.
22. Gascoyne RD, Adomat SA, Krajewski S, Krajewska M, Horsman DE, Tolcher AW, O'Reilly SE, Hoskins P, Coldman AJ, Reed JC, Connors JM. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997; 90: 244-251.
23. Hardingham JE, Kotasek D, Sage RE, Dobrovic A, Gooley T, Dale BM. Molecular detection of residual lymphoma cells in peripheral blood stem cell harvests and following autologous transplantation. Bone Marrow Transplant 1993; 11: 15-20.
24. Negrin RS, Kiem HP, Schmidt-Wolf IG, Blume KG, Cleary ML. Use of the polymerase chain reaction to monitor the effectiveness of ex vivo tumor cell purging. Blood 1991; 77: 654-660.
25. Scholten C, Hilgarth B, Hilgarth M, Jaeger U, Greinix HT, Mannhalter C. Predictive value of clone-specific CDR3 PCR in high-grade non-Hodgkin's lymphoma: long-term persistence of a clone-specific rearrangement in a patient with secondary high-grade NHL in remission after high-dose therapy. Br J Haematol 1997; 97: 246-247.
26. Cave H, Van Der Werft Ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, Bakkus M, Thielemans K, Grandchamp B, Vilmer E. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. New Engl J Meet 1998; 339: 591-598.
27. Cross NC. Quantitative PCR techniques and applications. Br J Haematol 1995; 89: 693-697.
28. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996; 6: 986-994.
29. Lin F, Cross NC. Molecular methods for monitoring malignant disease after bone marrow transplantation. Curr Opin Hematol 1995; 2: 460-467.
30. Billadeau D, Blackstadt M, Greipp P, Kyle RA, Oken MM, Kay N, Van Ness B. Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: a technique for sequential quantitation of residual disease. Blood 1991; 78: 3021-3024.
31. Gerard CJ, Olsson K, Ramanathan R, Reading C, Hanania EG. Improved quantitation of minimal residual disease in multiple myeloma using real-time polymerase chain reaction and plasmid-DNA complementarity determining region III standards. Cancer Res 1998; 58: 3957-3964.
32. Luthra R, McBride JA, Cabanillas F, Sarris A. Novel 5′ exonuclease-based real-time PCR assay for the detection of t(14;18)(q32;q21) in patients with follicular lymphoma. Am J Pathol 1998; 153: 63-68.
33. Dölken L, Schüler F, Dölken G. Quantitative detection of t(14;18)-positive cells by real-time quantitative PCR using fluorogenic probes. Biotechniques 1998; 6: 1058-1064.
34. Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res 1996; 6: 995-1001.
35. Holland PM, Abramson RD, Watson R, Gelfand DH. Detection of specific polymerase chain reaction product by utilizing the 5′→3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci USA 1991; 88: 7276-7280.
36. Lee MS, Chang KS, Cabanillas F, Freireich EJ, Trujillo JM, Stass SA. Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science 1987; 237: 175-178.
37. Livak KJ, Flood SJ, Marmaro J, Giusti W, Deetz K. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Meth Appl 1995; 4: 357-362.
38. Meeker TC, Sellers VV, Harvey R, Withers D, Carey K, Xiao H, Block AM, Dadey B, Han T. Cloning of the t(11;14)(q13;q32) translocation breakpoints from two human leukemia cell lines. Leukemia 1991; 5: 733-737.
39. Frank TS, Svoboda-Newman SM, Hsi ED. Comparison of methods for extracting DNA from formalin-fixed paraffin sections for nonisotopic PCR. Diagn Mol Pathol 1996; 5: 220-224.
40. Poteat HT, Sklar J. A simplified polymerase chain reaction assay for detection of chromosomal translocations in hematologic malignancies. Diagn Mol Pathol 1997; 6: 3-9.
41. +/Lin-peripheral blood stem cells (PBSC) in patients (PTS) with non-Hodgkin's lymphoma (NHL). Blood 1998; 12: 726a (Abstr).
42. Ji W, Qu GZ, Ye P, Zhang XY, Halabi S, Ehrlich M. Frequent detection of bcl-2/JH translocations in human blood and organ samples by a quantitative polymerase chain reaction assay. Cancer Res 1995; 55: 2876-2882.
43. Gribben JG, Freedman AS, Woo SD, Blake K, Shu RS, Freeman G, Lontine JA, Pinkus JS, Nadler LM. All advanced stage nonHodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 1991; 78: 3275-3280.
44. Liu Y, Hernandez AM, Shibata D, Cortopassi GA. BCL2 translocation frequency rises with age in humans. Proc Natl Acad Sci USA 1994; 91: 8910-8914.
45. Limpens J, Stad R, Vos C, de Vlaam C, de Jong D, van Ommen GJ, Schuring E, Kluin PM. Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood 1995; 85: 2528-2536.